Tactile Systems Technology INC 8-K filings

Tactile Systems Technology, Inc. has entered an exclusive U.S. distribution agreement with ElastiMed, Inc. for the MyoSleeve wearable compression device targeting VA and DoD patients.

Tactile Systems Technology, Inc. stockholders elected directors, ratified auditors, and approved a certificate of incorporation amendment at the 2026 Annual Meeting.

Tactile Systems Technology, Inc. announced a 23% year-over-year revenue increase to $75.3 million in Q1 2026, alongside improved gross margin and a shift to positive Adjusted EBITDA.

Tactile Systems Technology, Inc. announced robust third-quarter 2025 financial results, exceeding prior guidance and authorizing a new $25 million share repurchase program.

Tactile Systems Technology, Inc. reported a 7.8% year-over-year revenue increase to $78.9 million in Q2 2025, while net income and Adjusted EBITDA declined, leading to an updated full-year financial outlook.

Tactile Systems Technology, Inc. has adopted the 2025 Equity Incentive Plan, authorizing the issuance of up to 1,850,000 shares, and elected directors at its 2025 Annual Meeting of Stockholders.

Tactile Systems Technology's Q1 2025 results show a slight revenue increase but a decrease in net income and adjusted EBITDA compared to the same period last year.

Tactile Systems Technology, Inc. announced positive financial results for Q4 and full year 2024, with revenue increasing by 10% in the fourth quarter and 7% for the full year.

Tactile Systems Technology, Inc. has appointed seasoned healthcare executive Laura King to its Board of Directors, effective January 13, 2025.

Tactile Medical announced a 5% year-over-year revenue increase for Q3 2024, alongside a new $30 million share repurchase program.

Tactile Medical announced a 7% year-over-year increase in total revenue and a significant improvement in profitability for the second quarter of 2024.

Tactile Systems Technology has agreed to a settlement in a shareholder derivative lawsuit, which includes implementing corporate governance reforms and paying approximately $0.5 million in fees and expenses.

Tactile Systems Technology, Inc. held its annual meeting, approving an amendment to its charter to limit officer liability and electing directors.

Tactile Medical announced its first quarter 2024 financial results, showing a 4% increase in total revenue and reaffirming its full-year 2024 revenue outlook.

Tactile Systems Technology, Inc. announced the retirement of CEO Dan Reuvers and the appointment of Sheri Dodd as the new CEO, along with preliminary Q1 2024 revenue of approximately $61 million.

Tactile Medical announced its fourth quarter and full year 2023 financial results, highlighting significant growth in revenue, net income, and adjusted EBITDA, alongside a positive outlook for 2024.